Physiologically Based Pharmacokinetic Modeling is a sophisticated approach in pharmacodynamics that integrates physiological parameters to predict drug behavior within the body. It considers factors such as organ function, blood flow, and tissue composition to simulate drug concentration changes over time accurately. Unlike traditional pharmacokinetic models, PBPK offers a more comprehensive understanding of drug interactions, absorption, distribution, metabolism, and excretion.
PBPK models enhance drug development by providing insights into variability among individuals and populations, aiding in dose optimization and safety assessments. They play a pivotal role in predicting drug-drug interactions and supporting regulatory decisions. By incorporating physiological realism, PBPK modeling contributes to refining dosage regimens, minimizing adverse effects, and expediting the development of new therapeutic agents. As a powerful tool, PBPK modeling continues to revolutionize the field of pharmacodynamics, fostering more precise and personalized approaches to drug design and administration.
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Bernd Blobel
University of Regensburg, Germany
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Srividya Narayanan
Northeastern University, United States
Maria Richards Brown
University College London, United Kingdom
Rassa Pegahi
UPSA, France
Hanieh Khalili
University of East London, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation